Jefferies Healthcare Conference John Bishop Chairman & CEO June 2, 2014 1 Cepheid © © Cepheid Forward-Looking Statement During the course of this presentation, we may make projections or other forward-looking statements regarding future events or the future financial performance of Cepheid. We wish to caution you that such statements are just projections and that actual events or results may differ materially. We refer you to the documents that we have filed from time to time with the SEC, specifically our last filed Forms 10-K and 10-Q. These documents contain and identify important factors that could cause the actual results to differ materially from those contained in these projections and forward looking statements. 2 © Cepheid Worldwide Market Growth by Segment Overall IVD sales are projected to grow at a 5.9% CAGR through 2017. Molecular Diagnostics will remain the highest growth segment. Total = $68.6 B +5.9% CAGR Total = $51.9 B Flow Cytometry Immunohematology Histology/Cytology Microbiology Molecular Diagnostics Hem/Coag Clinical Chemistry Segment CAGR % Point of Care (Whole Blood Glucose) 2.3% Point of Care (All other) 8.1% Immunoassays 5.9% Clinical Chemistry 3.4% Hematology/Coagulation 3.0% Molecular Diagnostics 11.9% Microbiology 5.0% Histology/Cytology 9.3% Immunohematology 4.4% Flow Cytometry 6.9% Total Market 5.9% Immunoassay Point of Care 3 Market Diagnostics International 3 Worldwide MDx Market Overview Two‐thirds of 2012 Molecular Diagnostics market revenue was from diagnostic virology and bacteriology. 2012 ($ Billion) Percent of Total Virology $1.7 37% Bacteriology $1.2 26% Genetics/Genomics $0.9 20% Blood Screening $0.8 17% Total Market $4.6 100% Discipline 4 Total Market: $4.6 Billion Market Diagnostics International 4 US MDx Laboratory Universe by CLIA Complexity The most significant trend in molecular laboratories during 2012 was the adoption of moderately complex tests by laboratories that had not performed molecular diagnostics in the past. Molecular Laboratories By Testing Menu Total = 2,006 Total = 1,830 ‐3% The reduction in labs performing LDTs is attributable to the availability of more FDA‐cleared assays such as the Roche TaqMan CMV and the BioFire Respiratory Panel The growth in moderately complex laboratories is the result of the adoption of Meridian and Cepheid assays. Although the BioFire panel is moderately complex it was adopted by labs that already performed one or more molecular assays Highly Complex, with LDT Highly Complex, no LDT Moderately Complex 5 +2% +39% Market Diagnostics International Q1 2014: A Solid Start to the Year • GeneXpert System Placements +78% ‒ Commercial Placements +45% • Clinical Revenue +26%, Commercial Clinical +19% ‒ Commercial Clinical Xpert Test Revenue +24%* ‒ International Commercial Clinical Revenue +47% • Continued Menu Execution ‒ Xpert HPV, Xpert Norovirus CE-IVD Release in Early April 6 © Cepheid * Normalized for Q113 Backorder-Related Revenue Strategic Drivers GLOBAL MARKET EXPANSION APPLICABLE MARKET EXPANSION MAINTAINING GROWTH LEADERSHIP BROAD MENU EXPANSION 7 © Cepheid Broad Menu Expansion 2 1 Systems Expansion Test Expansion 3 8 © Cepheid Remote Connectivity and Data Management Development of Disease Portfolio Other Genetic Disease Oncology Cervical Breast Bladder Infectious Disease Bacterial Viral 9 © Cepheid Prostate Lung Develop The Most Compelling Test Menu Offering…. Available Now 14 Tests 16 Tests 10 MRSA Surveillance SA Nasal Complete C. diff & C. diff/Epi vanA for VRE MRSA/SA SSTI MRSA/SA Blood Culture EV Flu MTB/RIF CT/NG GBS & GBS Lim Broth Factor II&V MRSA Surveillance SA Nasal Complete C. diff/Epi vanA/vanB for VRE MRSA/SA SSTI MRSA/SA Blood Culture Norovirus (NEW!) EV Flu MTB/RIF CT & CT/NG GBS Factor II&V BCR-ABL Monitor HPV (Cervical CA) (NEW!) © Cepheid 2014-2015 19 Tests 24 Tests 2016-17 Norovirus Carba-R MRSA Surveillance-Next Gen Flu/RSV CW Flu/RSV Trichomonas 33 Carba-R Trichomonas MRSA Surveillance-Next Gen Flu/RSV HIV Quant HIV Qualitative HCV Quant BCR-ABL Ultra Bladder CA Monitor/Symptom 33 Tests Tests 2018-19 SA Nasal Complete-Next Gen Pertussis Gastro Panel HSV 1/2 Typing Vaginitis CW Vaginitis CW CT/NG HPV (Cervical CA) HIV Quant HCV Quant HBV Quant BCR-ABL Ultra Breast CA Stratifier Bladder CA Monitor Bladder CA Symptomatic 39 SA Nasal Complete-Next Gen Group A/C Strep Meningitis/Encephalitis Pertussis Gastro Panel HSV 1/2 Typing Vaginitis GBS Ultra HBV Quant Breast CA Stratifier Breast CA Signature 36 Notes: Targeted Test Menu Subject to Revision; CW = CLIA-Waived Tests in Italics Represent Product Improvements and are Excluded from Total Test Counts Group A/C Strep Meningitis/Encephalitis Tests GBS Ultra CW GBS Ultra CW Group A/C Strep CW HPV (Cervical CA) Breast CA Signature Tests Pancreatic CA Monitor EBV / NPC Screen EBV / NPC Monitor = US Tests = International Tests Develop The Most Compelling Test Menu Offering…. Available Now 14 Tests 16 Tests 11 2014-2015 MRSA Surveillance SA Nasal Complete C. diff & C. diff/Epi vanA for VRE MRSA/SA SSTI MRSA/SA Blood Culture EV Flu MTB/RIF CT/NG GBS & GBS Lim Broth Factor II&V Norovirus Norovirus 19 Carba-R 19 Tests Carba-R MRSA Surveillance-Next Gen MRSA Surveillance SA Nasal Complete C. diff/Epi vanA/vanB for VRE MRSA/SA SSTI MRSA/SA Blood Culture Norovirus (NEW!) EV Flu MTB/RIF CT & CT/NG GBS Factor II&V HPV (Cervical CA) (NEW!) BCR-ABL Monitor 2424Carba-R Carba-R Trichomonas Tests MRSA Surveillance-Next Gen © Cepheid Tests 2016-17 33 Tests MRSA Surveillance-Next Gen Flu/RSV CWFlu/RSV Flu/RSV Trichomonas CW Flu/RSV Trichomonas Tests Trichomonas 33 Tests Flu/RSV MRSA Surveillance-Next Gen HIV Quant Flu/RSV HIV Qualitative Quant HCVHIV Quant HIV Qualitative BCR-ABL Ultra HCVCAQuant Bladder Monitor/Sympt Bladder CA Monitor/Sympt BCR-ABL Ultra 2018-19 SA Nasal Complete-Next Gen Pertussis Gastro Panel HSV 1/2 Typing Vaginitis CW Vaginitis CW CT/NG BHPV (Cervical CA) HIV Quant HCV Quant HBV Quant CR-ABL Ultra Breast CA Stratifier Bladder CA Monitor Bladder CA Symptomatic 39 SA Nasal Complete-Next Gen Group A/C Strep Meningitis/Encephalitis Pertussis Gastro Panel HSV 1/2 Typing Vaginitis GBS Ultra HBV Quant Breast CA Stratifier Breast CA Signature 36 Notes: Targeted Test Menu Subject to Revision; CW = CLIA-Waived Tests in Italics Represent Product Improvements and are Excluded from Total Test Counts Group A/C Strep Meningitis/Encephalitis Tests GBS Ultra CW GBS Ultra CW Group A/C Strep CW HPV (Cervical CA) Breast CA Signature Tests Pancreatic CA Monitor EBV / NPC Screen EBV / NPC Monitor = US Tests = International Tests GeneXpert System Enables Broad Range of Oncology Opportunities ANY other validated RNA expression signature Breast CA Recurrence Signature Measure many targets simultaneously BCR-ABL Monitor (CML) Breast CA Classifier Sensitively detect translocations in blood Decentralized Path using FFPE tissue specimens Oncology Oncology Product Product Development Development Using UsingqPCR qPCR Prostate CA Recurrence Signature Bladder CA Screen At-Risk Others Bladder CA Symptomatic Bladder CA Monitor 12 © Cepheid Quantitate RNA targets in urine Quantitate mutations in ctDNA KRAS Pancreatic CA Monitor EGFR, ALK, KRAS Lung CA Monitor Establishing A Full Global Market Presence 13 © Cepheid Direct Direct & Emerging Markets Distributed Distributed & Emerging Markets Emerging Markets Expanding Scope of Applicable Markets GX-1 Infinity 80 GX-2 Hospitals Infinity 48s GX-4 GX-16 14 © Cepheid Expanding Scope of Applicable Markets Infinity 80 Independent Labs Infinity 48s 15 © Cepheid Industry Leading Throughput and Operating Efficiency 2:1 Advantage Infinity-80 Gen Probe Tigris CT/NG Testing Over One 8-Hour shift 16 © Cepheid 3:1 4:1 Advantage Gen Probe Panther Advantage BD Viper 4:1 Advantage Roche Cobas Taqman 96 4:1 Advantage Abbott m2000 Menu Application on High Throughput Systems Manufacturer Test Menu US:14 Cepheid EU:17 US: 9 Roche EU:17 (6800, 8800)* US: 6 Hologic EU: 6 (Tigris) US: 2 Qiagen EU: 2 (QiaSymphony RCU) Becton Dickinson EU: 4 (Viper) US: 8 Abbott EU:14 (m2000) * Roche 6600/8800 not yet released. 17 © Cepheid US: 4 On Line Test Capability Unlimited 3 4 1 1 1 Expanding Scope of Applicable Markets GX-1 GX-2 Alternate Sites • POL’s • Cruise Ships • Urgent Care • Home • Nursing Homes • Retail Outlets 18 © Cepheid GX-4 We are a better way. Cepheid NASDAQ: CPHD Questions? Contact Investor Relations: [email protected] or tel. (408) 400 8329 19 © Cepheid
© Copyright 2024 ExpyDoc
